[{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Acquisition","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Citrine Medicine","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Partnership","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Citrine Medicine","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Citrine Medicine"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Eton Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ Eton Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Eton Pharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"EffRx Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"UNITED KINGDOM","productType":"Steroid","year":"2020","type":"Licensing Agreement","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Endocrinology","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Oral Capsule","sponsorNew":"Diurnal Group \/ EffRx Pharmaceuticals","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ EffRx Pharmaceuticals"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"},{"orgOrder":0,"company":"Diurnal Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Steroid","year":"2021","type":"Inapplicable","leadProduct":"Hydrocortisone","moa":"Glucocorticoid receptor","graph1":"Genetic Disease","graph2":"Approved FDF","graph3":"Diurnal Group","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Capsule, Modified Release","sponsorNew":"Diurnal Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Diurnal Group \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Diurnal Group

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The submission for the MHRA is based on the data from the Company’s Phase 3 study, an open-label safety extension study of Chronocort® and written formal Scientific Advice received in April 2019 confirming the clinical and regulatory pathway for Chron...

                          Product Name : Alkindi Sprinkle

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          December 01, 2021

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Efmody® is a preparation of hydrocortisone that has been specifically designed for patients with CAH, a rare condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase.

                          Product Name : Alkindi Sprinkle

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          September 13, 2021

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Efmody® is a preparation of hydrocortisone that has been specifically designed for patients with CAH, an orphan condition caused by deficiency of adrenal enzymes, most commonly 21-hydroxylase.

                          Product Name : Alkindi Sprinkle

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          May 28, 2021

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The Phase 3 study results published by the JCEM found that although the standard-deviation-score-focused primary endpoint of the study was missed, Chronocort® improved morning and early afternoon biochemical control for adults with CAH over standard glu...

                          Product Name : Alkindi Sprinkle

                          Product Type : Steroid

                          Upfront Cash : Inapplicable

                          February 02, 2021

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Citrine will be responsible for obtaining registration for Alkindi® as a treatment for paediatric patients in China and for all commercialisation activities, including pricing and reimbursement.

                          Product Name : Alkindi Sprinkle

                          Product Type : Steroid

                          Upfront Cash : $0.5 million

                          January 27, 2021

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Citrine Medicine

                          Deal Size : $13.2 million

                          Deal Type : Licensing Agreement

                          blank

                          06

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Eton Pharmaceuticals Canadian rights to ALKINDI® SPRINKLE from Diurnal Group plc. Eton Pharmaceuticals currently commercializes ALKINDI® SPRINKLE in the United States as a replacement therapy for Adrenocortical Insufficiency (AI) in children under 17 y...

                          Product Name : Alkindi Sprinkle

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          January 14, 2021

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : Eton Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Acquisition

                          blank

                          07

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The $1.25 million milestone payment has been triggered as a result of the recent European Commission’s approval for Efmody® (hydrocortisone modified-release hard capsules) and the attainment by Citrine of certain development milestones in China for A...

                          Product Name : Alkindi Sprinkle

                          Product Type : Steroid

                          Upfront Cash : $1.0 million

                          January 06, 2021

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Approved FDF

                          Sponsor : Citrine Medicine

                          Deal Size : $2.2 million

                          Deal Type : Partnership

                          blank

                          08

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : Under the terms of the agreement EffRx has received the exclusive rights to register and commercialize Alkindi® in Switzerland.

                          Product Name : Alkindi Sprinkle

                          Product Type : Steroid

                          Upfront Cash : Undisclosed

                          October 21, 2020

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Approved FDF

                          Sponsor : EffRx Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          09

                          BePharma
                          Not Confirmed
                          BePharma
                          Not Confirmed

                          Details : The acquisition advanced Eton’s leadership in pediatric rare diseases products providing a $100 million market opportunity.

                          Product Name : Alkindi Sprinkle

                          Product Type : Steroid

                          Upfront Cash : $3.5 million

                          March 27, 2020

                          Lead Product(s) : Hydrocortisone

                          Therapeutic Area : Endocrinology

                          Highest Development Status : Phase III

                          Sponsor : Eton Pharmaceuticals

                          Deal Size : $7.5 million

                          Deal Type : Licensing Agreement

                          blank